Bausch Health Companies Inc. (BHC) Key Metrics
BHC valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.36B
- Enterprise value
- $21.09B
- P/E (TTM)
- —
- Forward P/E
- 1.3
- PEG ratio
- 0.01
- Price / sales
- 0.2 10-yr median 0.6
- Price / book
- 18.8 10-yr median 2.4
- EV / EBITDA
- 10.3 10-yr median 8.7
- Dividend yield
- —
- Beta
- 0.37
BHC key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBHC valuation Price multiples at each fiscal year-end price.
P/E ratio
16.6
2025 · hover or tap a bar for each year
20162025
Price / sales−17.6%
0.3
2025 · hover or tap a bar for each year
20162025
EV / EBITDA−6.1%
7.1
2025 · hover or tap a bar for each year
20162025
Price / free cash flow+10.4%
2.6
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−4.0 pts
38.5%
2025 · hover or tap a bar for each year
20162025
BHC returns How much profit the business earns on the capital it uses.
Return on invested capital+1.8 pts
5.6%
2025 · hover or tap a bar for each year
20162025
Return on assets+0.8 pts
0.6%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−3.3 pts
9.8%
2025 · hover or tap a bar for each year
20162025
Cash conversion (OCF / net income)
8.92
2025 · hover or tap a bar for each year
20162025
Asset turnover+8.7%
0.39
2025 · hover or tap a bar for each year
20162025
BHC per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+4.7%
$27.38
2025 · hover or tap a bar for each year
20162025
Earnings per share
$0.42
2025 · hover or tap a bar for each year
20162025
Free cash flow per share−21.9%
$2.67
2025 · hover or tap a bar for each year
20162025
Book value per share
−$1.47
2025 · hover or tap a bar for each year
20162025
Shares outstanding+1.9%
375.0M
2025 · hover or tap a bar for each year
20162025
BHC financial health Debt, liquidity and how easily interest is covered.
Net debt−$760.3M
$19.88B
2025 · hover or tap a bar for each year
20162025
Net debt / EBITDA−0.33
6.26
2025 · hover or tap a bar for each year
20162025
Current ratio+72.2%
1.47
2025 · hover or tap a bar for each year
20162025
Interest coverage+22.3%
1.4
2025 · hover or tap a bar for each year
20162025
Debt / assets−2.1%
0.81
2025 · hover or tap a bar for each year
20162025
BHC efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+1 days
80 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−11 days
195 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−14 days
76 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+5 days
199 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+0.4 pts
3.9%
2025 · hover or tap a bar for each year
20162025
BHC valuation history
Fiscal year-endToday10-year median
BHC returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BHC debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BHC cash returned to shareholders
DividendsBuybacksFree cash flow
BHC price vs earnings per share
Share price at year-endEPS (right axis)
BHC key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.61B | $2.97B | $2.93B | $2.27B | $9.91B | $7.38B | $10.53B | $6.46B | $7.31B | $5.04B |
| Enterprise value | $22.49B | $23.61B | $24.37B | $22.48B | $32.03B | $30.76B | $33.19B | $30.05B | $32.03B | $34.35B |
| P/E ratio | 16.6 | — | — | — | — | — | — | — | 3.0 | — |
| Price / sales | 0.3 | 0.3 | 0.3 | 0.3 | 1.2 | 0.9 | 1.2 | 0.8 | 0.8 | 0.5 |
| Price / book | — | — | — | — | — | 12.2 | 9.9 | 2.4 | 1.2 | 1.6 |
| Price / free cash flow | 2.6 | 2.4 | 3.9 | — | 8.7 | 9.2 | 8.6 | 5.1 | 3.7 | 2.8 |
| Price / operating cash flow | 1.9 | 1.9 | 2.8 | — | 6.9 | 6.6 | 7.0 | 4.3 | 3.2 | 2.4 |
| EV / sales | 2.2 | 2.5 | 2.8 | 2.8 | 3.8 | 3.8 | 3.9 | 3.6 | 3.7 | 3.6 |
| EV / EBITDA | 7.1 | 7.5 | 8.4 | 7.8 | 9.8 | 9.8 | 9.7 | 9.1 | 9.4 | 8.4 |
| EV / free cash flow | 22.4 | 18.7 | 32.1 | — | 28.0 | 38.3 | 27.1 | 23.7 | 16.4 | 19.1 |
| Earnings yield | 6.0% | −1.6% | −20.2% | −9.9% | −9.6% | −7.6% | −16.9% | −64.2% | 32.9% | −47.8% |
| Free cash flow yield | 38.5% | 42.5% | 26.0% | −43.8% | 11.5% | 10.9% | 11.6% | 19.6% | 26.7% | 35.6% |
| Dividend yield | — | — | — | 1.4% | — | — | — | — | 0.2% | 0.2% |
| Shareholder yield (dividends + buybacks) | — | 0.9% | 0.8% | 2.7% | 0.5% | 0.4% | 0.4% | 0.2% | 0.3% | 0.4% |
| Share price at fiscal year-end | $6.95 | $8.06 | $8.02 | $6.28 | $27.61 | $20.80 | $29.92 | $18.47 | $20.78 | $14.52 |
| Per share | ||||||||||
| Revenue per share | $27.38 | $26.15 | $24.00 | $22.44 | $23.50 | $22.61 | $24.43 | $23.95 | $24.80 | $27.85 |
| Earnings per share | $0.42 | −$0.12 | −$1.62 | −$0.62 | −$2.64 | −$1.57 | −$5.06 | −$11.86 | $6.83 | −$6.94 |
| Operating cash flow per share | $3.73 | $4.34 | $2.83 | −$2.01 | $3.97 | $3.13 | $4.26 | $4.29 | $6.51 | $6.01 |
| Free cash flow per share | $2.67 | $3.42 | $2.08 | −$2.75 | $3.18 | $2.26 | $3.47 | $3.62 | $5.55 | $5.17 |
| Cash per share | $3.53 | $3.21 | $2.60 | $1.56 | $1.62 | $1.70 | $9.21 | $2.06 | $2.05 | $1.56 |
| Book value per share | −$1.47 | −$3.48 | −$2.80 | −$1.91 | −$0.09 | $1.70 | $3.02 | $7.81 | $16.63 | $9.08 |
| Tangible book value per share | −$43.83 | −$48.69 | −$51.14 | −$49.83 | −$54.16 | −$58.83 | −$63.23 | −$64.05 | −$70.94 | −$90.77 |
| Dividends per share | — | — | — | $0.09 | — | — | — | — | $0.05 | $0.03 |
| Capex per share | $1.06 | $0.92 | $0.75 | $0.74 | $0.79 | $0.87 | $0.79 | $0.67 | $0.96 | $0.84 |
| Debt per share | $56.55 | $59.31 | $61.35 | $57.36 | $63.26 | $67.54 | $73.54 | $69.47 | $72.33 | $85.94 |
| Shares outstanding | 375.0M | 368.0M | 364.9M | 362.0M | 358.9M | 355.0M | 352.1M | 349.9M | 351.8M | 347.3M |
| Change in shares outstanding | +1.9% | +0.8% | +0.8% | +0.9% | +1.1% | +0.8% | +0.6% | −0.5% | +1.3% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | — | −67.0% | −93.9% | −96.7% | 53.4% | −53.2% |
| Return on invested capital (ROIC) | 5.6% | 3.9% | 3.8% | 1.7% | 1.5% | 2.2% | −0.6% | −6.6% | 0.3% | −1.3% |
| Return on assets (ROA) | 0.6% | −0.2% | −2.2% | −0.8% | −3.1% | −1.7% | −5.8% | −12.8% | 5.9% | −5.2% |
| Return on tangible assets | 1.5% | −0.5% | −6.1% | −2.7% | −9.7% | −5.8% | −16.9% | −180.0% | 35.9% | −27.2% |
| Free cash flow margin | 9.8% | 13.1% | 8.7% | −12.3% | 13.6% | 10.0% | 14.2% | 15.1% | 22.4% | 18.6% |
| Income quality (OCF / net income) | 8.92 | — | — | — | — | — | — | — | 0.95 | — |
| Financial health | ||||||||||
| Total debt | $21.21B | $21.83B | $22.39B | $20.77B | $22.70B | $23.98B | $25.89B | $24.30B | $25.44B | $29.85B |
| Cash & short-term investments | $1.32B | $1.18B | $947.0M | $564.0M | $582.0M | $605.0M | $3.24B | $721.0M | $720.0M | $542.0M |
| Net debt | $19.88B | $20.65B | $21.44B | $20.20B | $22.12B | $23.37B | $22.65B | $23.58B | $24.72B | $29.30B |
| Debt / equity | — | — | — | — | — | 39.63 | 24.36 | 8.89 | 4.35 | 9.47 |
| Debt / assets | 0.81 | 0.82 | 0.82 | 0.81 | 0.78 | 0.77 | 0.76 | 0.89 | 0.68 | 0.69 |
| Net debt / EBITDA | 6.26 | 6.59 | 7.43 | 7.02 | 6.79 | 7.45 | 6.63 | 7.11 | 7.24 | 7.20 |
| Current ratio | 1.47 | 0.86 | 1.30 | 1.08 | 1.08 | 1.09 | 1.12 | 0.19 | 1.11 | 1.41 |
| Quick ratio | 1.08 | 0.62 | 0.94 | 0.80 | 0.89 | 0.86 | 0.94 | −0.06 | 0.87 | 1.11 |
| Interest coverage | 1.4 | 1.1 | 0.7 | 0.3 | 0.3 | 0.4 | -0.1 | -1.4 | 0.1 | -0.3 |
| Working capital | $1.97B | −$978.0M | $1.29B | $306.0M | $409.0M | $429.0M | $721.0M | −$3.11B | $478.0M | $1.47B |
| Invested capital | $19.33B | $19.37B | $20.42B | $19.51B | $22.09B | $23.98B | $23.71B | $26.32B | $30.57B | $32.46B |
| Tangible asset value | −$15.51B | −$16.96B | −$17.72B | −$17.09B | −$19.44B | −$20.88B | −$22.19B | −$27.37B | −$24.86B | −$31.42B |
| Net current asset value | −$19.80B | −$21.07B | −$21.84B | −$21.18B | −$23.63B | −$25.25B | −$25.76B | −$28.95B | −$26.81B | −$35.19B |
| Graham number | — | — | — | — | — | — | — | — | $50.56 | — |
| Graham net-net per share | −$58.79 | −$63.21 | −$66.36 | −$63.47 | −$74.75 | −$79.60 | −$78.25 | −$77.43 | −$81.61 | −$107.43 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $31.0M | — | — | — | — | $18.0M | $9.0M |
| Share buybacks (net) | — | $26.0M | $24.0M | $31.0M | $52.0M | $30.0M | $40.0M | $10.0M | $4.0M | $11.0M |
| Dividend payout ratio | — | — | — | — | — | — | — | — | 0.7% | — |
| Dividends + buybacks / free cash flow | — | 2.1% | 3.2% | — | 4.5% | 3.7% | 3.3% | 0.8% | 1.1% | 1.1% |
| Capex / revenue | 3.9% | 3.5% | 3.1% | 3.3% | 3.4% | 3.8% | 3.2% | 2.8% | 3.9% | 3.0% |
| Capex / operating cash flow | 28.4% | 21.1% | 26.4% | — | 19.8% | 27.8% | 18.5% | 15.7% | 14.7% | 13.9% |
| Capex / depreciation | 0.33 | 0.27 | 0.22 | 0.19 | 0.18 | 0.17 | 0.13 | 0.08 | 0.12 | 0.10 |
| Stock-based compensation / revenue | 2.1% | 1.6% | 1.5% | 1.6% | 1.5% | 1.3% | 1.2% | 1.0% | 1.0% | 1.7% |
| R&D / revenue | 6.1% | 6.6% | 6.9% | 6.5% | 5.6% | 6.0% | 6.0% | 5.3% | 4.2% | 4.8% |
| SG&A / revenue | 33.5% | 34.1% | 33.1% | 31.2% | 29.5% | 29.5% | 29.7% | 29.5% | 29.6% | 28.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 79.8 | 78.5 | 78.9 | 80.1 | 72.5 | 77.7 | 78.6 | 87.0 | 97.2 | 98.2 |
| Days of inventory on hand | 195.1 | 205.9 | 187.8 | 160.8 | 159.1 | 178.6 | 158.5 | 153.9 | 151.1 | 164.4 |
| Days payables outstanding | 76.0 | 90.2 | 88.4 | 71.6 | 56.7 | 68.2 | 71.0 | 60.2 | 49.3 | 53.8 |
| Cash conversion cycle (days) | 198.9 | 194.2 | 178.4 | 169.3 | 174.9 | 188.1 | 166.1 | 180.6 | 198.9 | 208.8 |
| Receivables turnover | 4.58 | 4.65 | 4.62 | 4.56 | 5.03 | 4.70 | 4.64 | 4.20 | 3.75 | 3.72 |
| Payables turnover | 4.80 | 4.05 | 4.13 | 5.09 | 6.44 | 5.35 | 5.14 | 6.06 | 7.40 | 6.79 |
| Inventory turnover | 1.87 | 1.77 | 1.94 | 2.27 | 2.29 | 2.04 | 2.30 | 2.37 | 2.42 | 2.22 |
| Asset turnover | 0.39 | 0.36 | 0.33 | 0.30 | 0.28 | 0.25 | 0.28 | 0.26 | 0.22 | 0.21 |
| Average receivables | $2.24B | $2.07B | $1.89B | $1.78B | $1.68B | $1.71B | $1.85B | $2.00B | $2.32B | $2.60B |
| Average payables | $627.5M | $687.5M | $620.0M | $464.0M | $372.0M | $420.0M | $457.0M | $388.0M | $344.5M | $379.0M |
| Average inventory | $1.61B | $1.57B | $1.32B | $1.04B | $1.04B | $1.10B | $1.02B | $991.0M | $1.05B | $1.16B |
| Intangibles / total assets | 60.4% | 62.7% | 64.5% | 67.5% | 66.5% | 68.9% | 68.9% | 91.6% | 82.2% | 79.7% |
Computed from BHC's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BHC valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Bausch Health traded at 16.6 times earnings. Bausch Health earned a return on invested capital of 5.6% in fiscal 2025. It ended the year with $21.2 billion of debt and $1.3 billion in cash and short-term investments, net debt of $19.9 billion. The share count rose 8.0% from 347.3M to 375.0M over 9 years.
See the BHC income statement, the BHC chart for price history, or the BHC stock overview for the latest quote and news.
BHC key metrics FAQ
What is Bausch Health's P/E ratio?
Bausch Health traded at 16.6 times earnings at the end of fiscal 2025.
What is Bausch Health's EV/EBITDA?
Bausch Health's enterprise value was 7.1 times EBITDA at the end of fiscal 2025 (enterprise value $22.5 billion, EBITDA $3.2 billion); the current EV/EBITDA is 10.3.
What is Bausch Health's ROIC?
Bausch Health's return on invested capital was 5.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Bausch Health have?
Bausch Health had total debt of $21.2 billion at the end of fiscal 2025 and $19.9 billion of net debt (6.26 times EBITDA).
What is Bausch Health's free cash flow yield?
Bausch Health generated $1.0 billion of free cash flow in fiscal 2025, a free cash flow yield of 38.5% on its market value at year-end ($2.6 billion).
What is Bausch Health's current ratio?
Bausch Health's current ratio was 1.47 at the end of fiscal 2025: current assets were 1.47 times current liabilities.